Charles Berkman S.'s most recent trade in OmniAb Inc was a trade of 13,542 Common Stock done . Disclosure was reported to the exchange on April 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 13,542 | 370,418 | - | 0 | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 13,542 | 112,497 | - | - | Restricted Stock Units | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 07 Apr 2025 | 7,206 | 363,212 | - | 2 | 14,412 | Common Stock |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 337,500 | 337,500 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 56,250 | 126,039 | - | - | Restricted Stock Units | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 15,615 | 83,330 | - | - | Restricted Stock Units | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 15,615 | 358,805 | - | - | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 13,541 | 69,789 | - | - | Restricted Stock Units | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 13,541 | 372,346 | - | - | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.68 per share. | 15 Feb 2025 | 8,215 | 364,131 | - | 3.7 | 30,231 | Common Stock |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.67 per share. | 15 Feb 2025 | 7,255 | 356,876 | - | 3.7 | 26,626 | Common Stock |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 45,294 | 368,679 | - | 0 | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 3.24 per share. | 17 Jan 2025 | 25,489 | 343,190 | - | 3.2 | 82,584 | Common Stock |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2024 | 15,621 | 331,407 | - | - | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2024 | 15,621 | 98,945 | - | - | Restricted Stock Units | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 4.13 per share. | 07 Dec 2024 | 8,022 | 323,385 | - | 4.1 | 33,131 | Common Stock |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2024 | 13,541 | 114,566 | - | - | Restricted Stock Units | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2024 | 13,541 | 299,571 | - | - | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 5.27 per share. | 07 Apr 2024 | 6,954 | 292,617 | - | 5.3 | 36,648 | Common Stock |
| OmniAb Inc | Berkman S. Charles | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 243,750 | 243,750 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | S. Berkman Charles | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 40,625 | 128,107 | - | - | Restricted Stock Units | |
| OmniAb Inc | S. Charles Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 15,624 | 287,941 | - | - | Common Stock | |
| OmniAb Inc | S. Charles Berkman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 15,624 | 93,180 | - | - | Restricted Stock Units | |
| OmniAb Inc | Charles Berkman S. | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 5,698 | 288,064 | - | - | Common Stock | |
| OmniAb Inc | Berkman Charles S. | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 5,698 | 87,482 | - | - | Restricted Stock Units | |
| OmniAb Inc | Berkman Charles S. | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.54 per share. | 15 Feb 2024 | 5,575 | 282,366 | - | 5.5 | 30,886 | Common Stock |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.54 per share. | 15 Feb 2024 | 2,034 | 286,030 | - | 5.5 | 11,268 | Common Stock |
| OmniAb Inc | S. Berkman Charles | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 17,556 | 108,804 | - | - | Restricted Stock Units | |
| OmniAb Inc | S. Berkman Charles | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 17,556 | 279,512 | - | - | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.25 per share. | 02 Jan 2024 | 7,195 | 272,317 | - | 6.3 | 44,969 | Common Stock |
| OmniAb Inc | Berkman Charles S. | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 15,622 | 126,360 | - | - | Restricted Stock Units | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2023 | 243,750 | 243,750 | - | - | Stock Option | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2023 | 40,625 | 414,564 | - | 0 | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 15 Feb 2023 | 5,404 | 376,105 | - | 3.8 | 20,535 | Common Stock |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 15 Feb 2023 | 2,166 | 373,939 | - | 3.8 | 8,231 | Common Stock |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 15 Feb 2023 | 1,973 | 381,509 | - | 3.8 | 7,497 | Common Stock |
| OmniAb Inc | Charles S. Berkman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 366,511 | 305,412 | - | - | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 52,587 | 0 | - | - | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 35,810 | 0 | - | - | Stock Option | |
| OmniAb Inc | Charles S. Berkman | Director, CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 35,810 | 35,810 | - | - | Stock Option | |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | Former Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 20,126 | 0 | - | - | Employee Stock Option (right to buy) | |
| OmniAb Inc | Charles S. Berkman | Director, CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 15,409 | 52,587 | - | 0 | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 15,043 | 0 | - | - | Stock Option | |
| OmniAb Inc | Charles S. Berkman | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 12,797 | 0 | - | - | Stock Option | |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | Former Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 11,944 | 23,825 (0%) | 0% | - | Common Stock | |
| OmniAb Inc | Charles S. Berkman | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 8,117 | 0 | - | - | Stock Option | |
| OmniAb Inc | Charles S. Berkman | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 6,076 | 0 | - | - | Stock Option | |
| OmniAb Inc | Charles S. Berkman | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 5,966 | 0 | - | - | Stock Option | |
| OmniAb Inc | Charles S. Berkman | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 3,627 | 0 | - | - | Stock Option | |
| OmniAb Inc | Charles S. Berkman | Director, CLO & Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 1,701 | 0 | - | - | Stock Option | |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 5,375 | 35,769 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 20,126 | 20,126 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 633 | 30,971 (0%) | 0% | 123.7 | 78,289 | Common Stock |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 577 | 30,394 (0%) | 0% | 123.7 | 71,363 | Common Stock |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 368 | 31,604 (0%) | 0% | 123.7 | 45,514 | Common Stock |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 3,836 | 34,128 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 2,401 | 30,292 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.68 per share. | 26 Jan 2022 | 1,326 | 31,972 (0%) | 0% | 113.7 | 150,740 | Common Stock |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.68 per share. | 26 Jan 2022 | 830 | 33,298 (0%) | 0% | 113.7 | 94,354 | Common Stock |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 442 | 27,891 (0%) | 0% | 172.5 | 76,227 | Common Stock |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 368 | 28,333 (0%) | 0% | 172.5 | 63,465 | Common Stock |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 205 | 28,701 (0%) | 0% | 172.5 | 35,354 | Common Stock |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Sale of securities on an exchange or to another person at price $ 178.50 per share. | 03 Feb 2021 | 18,097 | 28,906 (0%) | 0% | 178.5 | 3,230,376 | Common Stock |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 6,955 | 6,955 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 3,491 | 47,003 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 2,401 | 44,342 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 1,335 | 42,450 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.01 per share. | 25 Jan 2021 | 830 | 43,512 (0%) | 0% | 156.0 | 129,488 | Common Stock |
| Ligand Pharmaceuticals, In... | Charles S. Berkman | SVP, Gen. Counsel & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.10 per share. | 25 Jan 2021 | 509 | 41,941 (0%) | 0% | 156.1 | 79,455 | Common Stock |